PL2055308T3 - Farmaceutyk do promowania funkcjonalnej regeneracji uszkodzonej tkanki - Google Patents

Farmaceutyk do promowania funkcjonalnej regeneracji uszkodzonej tkanki

Info

Publication number
PL2055308T3
PL2055308T3 PL07830867T PL07830867T PL2055308T3 PL 2055308 T3 PL2055308 T3 PL 2055308T3 PL 07830867 T PL07830867 T PL 07830867T PL 07830867 T PL07830867 T PL 07830867T PL 2055308 T3 PL2055308 T3 PL 2055308T3
Authority
PL
Poland
Prior art keywords
pharmaceutical
damaged tissue
promoting functional
functional regeneration
regeneration
Prior art date
Application number
PL07830867T
Other languages
English (en)
Inventor
Katsuto Tamai
Takehiko Yamazaki
Yasufumi Kaneda
Original Assignee
Genomix Co., Ltd.
Osaka University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genomix Co., Ltd., Osaka University filed Critical Genomix Co., Ltd.
Publication of PL2055308T3 publication Critical patent/PL2055308T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Rheumatology (AREA)
PL07830867T 2006-10-30 2007-10-30 Farmaceutyk do promowania funkcjonalnej regeneracji uszkodzonej tkanki PL2055308T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006293582 2006-10-30
EP07830867.3A EP2055308B1 (en) 2006-10-30 2007-10-30 Pharmaceutical for promoting functional regeneration of damaged tissue

Publications (1)

Publication Number Publication Date
PL2055308T3 true PL2055308T3 (pl) 2017-11-30

Family

ID=39344234

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07830867T PL2055308T3 (pl) 2006-10-30 2007-10-30 Farmaceutyk do promowania funkcjonalnej regeneracji uszkodzonej tkanki

Country Status (13)

Country Link
US (2) US20090202500A1 (pl)
EP (1) EP2055308B1 (pl)
JP (2) JP5308161B2 (pl)
KR (2) KR20140115373A (pl)
CN (1) CN101374538A (pl)
AU (1) AU2007315073A1 (pl)
CA (1) CA2636788A1 (pl)
DK (1) DK2055308T3 (pl)
ES (1) ES2629086T3 (pl)
HU (1) HUE035043T2 (pl)
PL (1) PL2055308T3 (pl)
PT (1) PT2055308T (pl)
WO (1) WO2008053892A1 (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5676253B2 (ja) * 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
JP5814549B2 (ja) * 2008-04-30 2015-11-17 株式会社ジェノミックス 損傷組織の機能的再生促進医薬
US8673580B2 (en) 2008-04-30 2014-03-18 Genomix Co., Ltd. Agent for recruitment of bone-marrow-derived pluripotent stem cell into peripheral circulation
JP5706081B2 (ja) * 2009-10-28 2015-04-22 株式会社ジェノミックス 埋め込み式生体内物質採取デバイス
JP5865703B2 (ja) * 2009-10-28 2016-02-17 株式会社ジェノミックス 骨髄間葉系および／または多能性幹細胞の血中動員による組織再生促進剤
JP5852773B2 (ja) * 2010-06-01 2016-02-03 ピアス株式会社 骨髄間葉系幹細胞の誘引剤の製造方法、骨髄間葉系幹細胞の誘引方法、及び、骨髄間葉系幹細胞の誘引剤を製造するための使用
PT3358011T (pt) * 2011-04-26 2020-04-23 Univ Osaka Péptido para induzir a regeneração de um tecido e a sua utilização
CN102864123B (zh) * 2011-07-06 2015-04-22 北京大学第三医院 一种外周血间充质干细胞的获得方法及其应用
US9688733B2 (en) 2012-10-25 2017-06-27 Genomix Co., Ltd. Method for treating spinal cord injury using HMGB1 fragment
ES2660420T3 (es) 2012-10-25 2018-03-22 Genomix Co., Ltd. Método novedoso para tratar infarto cardiaco utilizando fragmento de HMGB1
CN103316378B (zh) * 2013-06-27 2014-07-16 重庆大学 一种hmgb 1修饰的骨组织工程支架材料及其制备方法
JP6288672B2 (ja) * 2014-03-28 2018-03-07 株式会社巴川製紙所 異方性光学フィルム
JP6452107B2 (ja) * 2014-09-05 2019-01-16 国立大学法人 東京大学 糖尿病性皮膚潰瘍治療のための多能性幹細胞
JP6941417B2 (ja) * 2016-02-04 2021-09-29 雪印メグミルク株式会社 軟骨機能改善剤
KR102359441B1 (ko) * 2016-06-29 2022-02-09 (주)아모레퍼시픽 지방세포 분화 촉진용 조성물 및 지방세포 분화 촉진 물질의 스크리닝 방법
TWI740964B (zh) * 2016-06-29 2021-10-01 南韓商愛茉莉太平洋股份有限公司 促進脂肪細胞分化之用途及篩選促進脂肪細胞分化物質之方法
EP3556378B1 (en) 2017-01-27 2025-03-12 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
CA3059544A1 (en) 2017-04-25 2018-11-01 Shionogi & Co., Ltd. Peptide for inducing regeneration of tissue, and use thereof
CN106957821B (zh) * 2017-04-26 2020-04-21 南京医科大学第二附属医院 一种调控间充质干细胞定向分化的方法
WO2019017355A1 (ja) * 2017-07-18 2019-01-24 株式会社資生堂 間葉系幹細胞誘引剤
CN111542335A (zh) 2017-12-01 2020-08-14 斯特姆里姆有限公司 炎症性肠病的治疗药
CN111868231B (zh) 2017-12-01 2024-05-31 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
US20210024594A1 (en) 2018-02-08 2021-01-28 StemRIM Inc. Therapeutic Agent for Psoriasis
WO2020071520A1 (ja) 2018-10-05 2020-04-09 株式会社ステムリム 間葉系幹細胞の動員活性を有するペプチド
US12304933B2 (en) 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
CA3286605A1 (en) 2018-11-04 2025-11-29 Fibrobiologics, Inc. Treatment of cachexia using fibroblast cells and products thereof
US20220023350A1 (en) * 2018-11-04 2022-01-27 Figene, Llc Treatment of cerebral hypoxia including stroke, chronic traumatic encephalopathy, and traumatic brain injury
CN109957015A (zh) * 2019-04-01 2019-07-02 中国人民解放军海军军医大学国家肝癌科学中心 一种hmgb1封闭性抗体的制备方法及其应用
JP7561348B2 (ja) * 2019-07-31 2024-10-04 株式会社ステムリム 間葉系幹細胞の増殖促進または減少抑制のための組成物
AU2020385059A1 (en) 2019-11-12 2022-06-02 Oxford University Innovation Limited Polypeptides related to HMGB1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
US20240018588A1 (en) * 2020-12-07 2024-01-18 Samsung Life Public Welfare Foundation Method for selecting mesenchymal stem cells having improved self-maintenance ability, and mesenchymal stem cells selected thereby
JP2024515805A (ja) * 2021-04-27 2024-04-10 アヴィータ・メディカル・インコーポレイテッド 新たに脱凝集された組織に由来する再生生物活性懸濁液および臨床治療における使用方法
WO2022243932A1 (en) 2021-05-19 2022-11-24 Oxford University Innovation Limited Polypeptides related to hmgb1 useful for promoting tissue regeneration, compositions comprising same, and uses thereof
US12570949B2 (en) 2022-12-27 2026-03-10 AVITA Medical Americas, LLC Systems and devices for wound therapy and related methods of use
DE202023002794U1 (de) 2022-12-27 2024-07-15 AVITA Medical Americas, LLC Kassette zur Herstellung einer regenerativen epidermalen Suspension
USD1112812S1 (en) 2023-12-22 2026-02-10 AVITA Medical Americas, LLC Tissue processing cartridge

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
JP3018313B2 (ja) * 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
ATE440602T1 (de) * 1999-07-28 2009-09-15 Univ Leland Stanford Junior Nicotinrezeptoragonisten in stammzellen und vorlaüferzellinduktion
KR20030032922A (ko) * 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
CA2467557A1 (en) * 2001-11-19 2003-05-30 Kyowa Hakko Kogyo Co., Ltd. Agent which mobilizes multipotential stem cells from tissues to peripheral blood
AU2003228099A1 (en) * 2002-07-03 2004-01-23 Centro Cardiologico Monzino S.P.A.-Irccs Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
WO2004061456A2 (de) * 2003-01-03 2004-07-22 Alcedo Biotech Gmbh Verwendungen von hmgb, hmgn, hmga proteinen
WO2004075855A2 (en) * 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
EP1608397B1 (en) * 2003-03-28 2008-10-15 Universite Laval S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
WO2005025604A2 (en) * 2003-09-10 2005-03-24 The General Hospital Corporation Use of hmgb and hmgb fragments to decrease specific immune response
JP2008507505A (ja) * 2004-07-20 2008-03-13 プロヴィンシア・イタリアーナ・デッラ・コングレガチォーネ・フィリ・デッリマコラータ・コンセチォーネ−イスティトゥト・デルモパティコ・デッリマコラータ−アイ・アール・シー・シー・エス 創傷治癒のためのｈｍｇｂ１の使用
KR100593397B1 (ko) * 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 ｐ 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2007015546A1 (ja) * 2005-08-04 2007-02-08 Genomix Co., Ltd 間葉系幹細胞誘導剤及び組織再生促進剤並びに間葉系幹細胞の調製方法
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
US7829097B2 (en) * 2006-02-06 2010-11-09 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Use of HMGB1 for protection against ischemia reperfusion injury
JP5676253B2 (ja) * 2008-04-30 2015-02-25 株式会社ジェノミックス 生体内機能的細胞の高効率採取法

Also Published As

Publication number Publication date
DK2055308T3 (en) 2017-07-17
EP2055308A4 (en) 2010-10-27
HUE035043T2 (en) 2018-05-02
CN101374538A (zh) 2009-02-25
EP2055308A1 (en) 2009-05-06
CA2636788A1 (en) 2008-05-08
JP2013227330A (ja) 2013-11-07
JPWO2008053892A1 (ja) 2010-02-25
US20090202500A1 (en) 2009-08-13
EP2055308B1 (en) 2017-05-10
US20240050460A1 (en) 2024-02-15
KR20090078304A (ko) 2009-07-17
WO2008053892A1 (en) 2008-05-08
AU2007315073A1 (en) 2008-05-08
JP5308161B2 (ja) 2013-10-09
PT2055308T (pt) 2017-07-05
ES2629086T3 (es) 2017-08-07
KR20140115373A (ko) 2014-09-30

Similar Documents

Publication Publication Date Title
PL2055308T3 (pl) Farmaceutyk do promowania funkcjonalnej regeneracji uszkodzonej tkanki
ZA200903598B (en) Lipase variants for pharmaceutical use
IL198663A0 (en) Tissue treatment methods
IL287975A (en) Skin care system
EP2020943A4 (en) SYSTEM FOR REMOVING HARD WEAVE
EP2049035A4 (en) NASAL TISSUE TREATMENT SYSTEMS
IL193747A0 (en) New therapeutic combinations for the treatment of depression
GB0725263D0 (en) Instrument for removing tissue
PL2087890T3 (pl) Preparat o przedłużonym uwalnianiu do terapii regeneracyjnej tkanki
EP2000169A4 (en) CATHETER FOR BLOOD EVACUATION
ZA200805761B (en) Pharmaceutical composition for the treatment of nail disease
EP2001489A4 (en) PHARMACEUTICAL COMPOSITIONS FOR PROMOTING HEALING
EP2213303A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CATARACT
GB0719248D0 (en) Compounds and methods for pharmaceutical use
GB0816650D0 (en) Therapeutic bone grwth and regeneration
IL197125A0 (en) Drug combinations for treating airway diseases
IL192933A0 (en) Benzoisoindole derivatives for the treatment of pain
EP2102231A4 (en) IMPROVED EXPRESSION SYSTEM FOR RECOMBINANT HUMAN ARGINASE I
ZA200900035B (en) Prophylactic or therapeutic agent for viral disease
FI20065514A0 (fi) Aktivoidut fibroblastit kudosvaurioiden hoitamiseksi
EP2129314A4 (en) DEVICE FOR TISSUE SEPARATION
EP2070541A4 (en) MEANS FOR PROMOTING REGENERATION OF HARD FABRIC
IL184236A0 (en) Glycine reuptake inhibitors for treatment of drug dependence
EP2210878A4 (en) THERAPEUTIC AGENT AGAINST TRPV1-MEDIATED DISEASES
IL177114A0 (en) Disposable swab